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Optimization of amino acid-stabilized erythropoietin parenteral 
formulation: In vitro and in vivo assessment
The aim of this study was to optimize the formulation of 
erythropoietin (EPO) using amino acids instead of human 
serum albumin (HSA) and to evaluate its in vivo stability in 
order to avoid the risk of viral contamination and antigenic-
ity. Diff erent EPO formulations were developed in such a 
way as to allow studying the eff ects of amino acids and sur-
factants on the EPO stability profi le. The main techniques 
applied for EPO analysis were ELISA, Bradford method, 
and SDS gel electrophoresis. The in vivo stability was evalu-
ated in a Balb-c mouse animal model. The results showed 
that the presence of surfactant was very useful in prevent-
ing the initial adsorption of EPO on the walls of vials and in 
minimizing protein aggregation. Amino acid combina-
tions, glycine with glutamic acid, provided maximum sta-
bility. Formulation F4 (containing glycine, glutamic acid 
and Tween 20) showed minimum aggregation and degrada-
tion and in vivo activity equivalent to commercially avail-
able HSA-stabilized EPO (Eprex®).
Keywords: erythropoietin (EPO), amino acids, human se-
rum albumin, protein stability, Bradford, ELISA, gel elec-
trophoresis
 
Erythropoietin (EPO) is a-glycoprotein hormone of 165 amino acids, with molecular 
mass of 35 KDa, which is 40 % glycosylated (1, 2). This glycosylated part is a prerequisite 
for biological activity and has an important role for stabilization of the tertiary structure 
(3). It is produced by the peritubular capillary endothelial cells in the kidney and a small 
amount is produced in the liver (4, 5). It stimulates division and diff erentiation of the pre-
cursors of red blood cells (RBCs) in the bone marrow to mature red blood cells and prevent 
their apoptosis (1).
EPO has various indications, including treatments of anemia associated with kidney 
diseases, anemia associated with bone marrow transplantation, iron defi ciency anemia, 
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cancer- or antitumor agent-related anemia, and AIDS-associated anemia (6–9). However, 
EPO has low stability and degrades in aqueous solutions (10); moreover, it adsorbs to the 
inner surface of the wall of the syringe, which contributes to its aggregation and denatur-
ation. Denaturation of EPO is generally irreversible. Thus, once denatured, EPO cannot 
recover its native properties. Further, the denatured protein structure is likely to cause 
hypersensitivity (11). Under such circumstances, various att empts have been made to in-
crease the stability of EPO in aqueous solution. Some protein formulations solved dena-
turation by a lyophilization method (12). However, lyophilization has a number of draw-
backs, including high manufacturing cost, the need of a large capacity freeze-dryer, and 
reconstitution prior to injection. Another approach is to incorporate protein stabilizers 
such as surfactants, like polysaccharides, serum albumin, macromolecules, amino acids 
and salts (11–14). Kawaguchi and Shimoda (13) introduced the use of stabilizers such as 
polyethylene glycol, proteins, saccharides, amino acids, and organic and inorganic salts to 
stabilize both lyophilized and aqueous formulations of EPO. The role of human serum 
albumin (HSA), dextran, cellulose and lecithin in preventing protein adsorption to the 
ampoule wall was described also by Kawaguchi and Shimoda (14). The recovery yield of 
EPO was improved from 16 to 69–98 % aft er storage for 2 hours at 20 °C (14). Konings et al. 
(15) reported the use of b-cyclodextrin as stabilizer in aqueous, lyophilized and spray-
dried powder formulations of EPO, but with a risk of renal toxicity due to the use of cyclo-
dextrin (15). Strickland (16) compared the stabilizing eff ect of HSA with other stabilizing 
agents such as benzyl alcohol, parabens, phenol or their combinations in diff erent paren-
teral EPO formulations. The results showed low stability compared to the EPO formulation 
with HSA. Yamazaki et al. (17) reported the use of an amino acid, such as leucine, serine, 
glutamic acid, arginine or histidine as a stabilizing agent instead of HSA or purifi ed gela-
tin; such formulations showed good stability. Stabilization with HSA carries a high risk of 
viral contamination, in addition to being more susceptible to allergic reactions. In Europe, 
the use of materials from human and animal sources as pharmaceutical additives is being 
increasingly restricted (11). For this reason, further studies are required for optimization 
of stable EPO formulations free from HSA.
The primary aim of this study was to optimize one or more aqueous parenteral EPO for-
mulations free from blood derived products and to prove their stability both in vitro and in vivo.
EXPERIMENTAL
Materials
Erythropoietin was a gift  from SPIMACO (Qassim, Saudi Arabia), Commassie blue 
was obtained from Merck (Germany), Poloxamer 188 NF, Sodium dodecyl sulphate and 
glycine were purchased from Sigma-Aldrich (USA), EPO ELISA kits from Roche (Basel, 
Switzerland). Silver staining kit was obtained from GE Healthcare Life Sciences, Sweden. 
All other chemicals and reagents were of pharmaceutical grade.
Methods
Preparation of standard erythropoietin formulation. – Thirteen EPO parenteral formula-
tions were prepared aseptically (Table I). All formulations contained 40 mg of EPO and 5 mg 
mannitol to adjust the tonicity. The components of each formulation were dissolved in a 
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small volume of sterile phosphate buff er saline pH 7 (PBS). Then, the volume was com-
pleted to give ingredient concentrations per one mL using PBS as shown in Table I. The 
fi nal solution was sterilized by membrane fi ltration using a 0.22-mm cutoff  cup fi lter. Vol-
ume of 1mL of each formulation was fi lled in a sterile standard glass vial. Sixty vials were 
prepared for each formulation. Factors such as the eff ects of amino acid and surfactant and 
their type on the stability profi le of EPO were investigated, resulting in various composi-
tions of formulations. A formulation containing 2.5 mg HSA alone with 40 mg EPO (F13) 
was included for comparison, since it has a similar composition to that of the currently 
marketed EPO formulation (Eprex®, 1000 IU/0.5 mL, Janssen-Cilag Company, Canada). The 
formulation contains HSA (0.25 %), sodium chloride, sodium citrate, citric acids, and benzyl 
alcohol (0.9 %) in injection water. One IU is equivalent to 7.9 ng EPO.
Accelerated stability testing. – Thirty vials from each formulation were stored for two 
months at 25 and 40 °C in stability cabinets thermostatically controlled to ± 1 °C. Samples 
of fi ve vials were taken from each formulation at each of the storage temperatures at time 
intervals of 0, 15, 30, 45 and 60 days. The samples were evaluated to detect EPO stability 
using the following analytical methods.
Bradford method. – This is a colorimetric analytical method applied for the quantitative 
determination of protein concentration, principally based on color transfer of a Coomassie 
dye from green or red (unbound) to blue (bound with protein). The intensity of color is 
proportional to the protein concentration (18). Simply, 1 mL of Bradford reagent was added 
to 100 mL of the sample and measured at lmax 595 nm.
Enzyme linked immunosorbent assay (ELISA). – EPO-ELISA kit was used to detect EPO 
concentration according to the protocol provided by the following procedures. A standard 
EPO stock solution was prepared at a concentration of 1000 ng mL–1. Then, serial dilutions 
were made to prepare concentrations of 10, 5, 2.5, 1.25 and 0.6 ng mL–1. All standard solu-
tions and EPO samples were incubated overnight in an ELISA plate pre-coated with rabbit 
polyclonal anti-hEPO capture antibody at 4 °C. Aft er rinsing, the EPO-antibody complex 
bound to the plate surface was detected with the peroxidase-conjugated secondary anti-
body (HRP). Aft er washing, tetra-methylbenzidine (TMB) was added for 10 minutes untill 
blue color started to come out. Finally, TMB solution was added to stop the reaction and 
absorption was measured at 450 nm.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). – SDS gel electro-
phoresis was used to detect any aggregation or degradation of EPO. Briefl y, samples were 
electrophoresed with freshly prepared 12 % polyacrylamide gel using an electrophoresis 
system (Hoefer SE 280 gel electrophoresis unit, Hoefer Inc., USA). Gel sheets were silver 
stained as previously described (19). First, the gel was prepared to eliminate the interfering 
substances and thus avert the possibility of high background and/or poor contrast. Then, 
gels were sensitized to increase the sensitivity and/or contrast. Consequently, the gel was 
impregnated with the silvering agent. Images were developed by adding a dilute formal-
dehyde solution. Finally, the reaction was stopped to prevent overdevelopment.
Western-blott ing. – It is a technique used to determine a specifi c protein by marking it 
with a proper antibody. Initially the samples were electrophoresed as described before, 
then the gel was blott ed electrophoretically onto a polyvinylidene fl uoride membrane and 
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assayed with rabbit polyclonal anti-hEPO capture antibody as the fi rst antibody. Then the 
detection was done using peroxidase-conjugated secondary antibody. The bands were vi-
sualized by adding TMB as enzyme substrate.
In vivo bioassay. – The studies were carried out using 8-week old male Balb/c mice, 
weighing from 16–18 g, obtained from the animal care house, Faculty of Pharmacy, King 
Saud University (Riyadh, KSA). All the animals were healthy and used for the fi rst time as 
experimental animals. The animals were housed in suitable cages with continuous food 
and water supply. The room temperature was adjusted to 20 ± 2 °C with twelve hours dark/
light intervals.
The animal experiments complied with the United States National Institute of Health 
(US NIH) Guide for the Care and Use of Laboratory Animals (NIH Publication No. 18–23, 
1985). The study protocol was approved by the Animal Care and Use Committ ee, College 
of Pharmacy. King Saud University (Riyadh, KSA).
The animals were divided into four groups, each containing 6 mice. A parallel study 
was performed where each group received one treatment by subcutaneous injection. 
Group one was a negative control group receiving sterile PBS. Groups 2, 3, and 4 received 
150 IU of EPO solution in PBS, Eprex® and F4, respectively. Four days aft er injection, 5 mL 
blood samples were collected from the tail vein and mixed with 1 mL Retic-count reagent. 
The ratio of reticulocytes to RBCs was measured using a fl ow-cytometer (Becton Dickin-
son FACSCalibur, Biosciences, USA). Data were analyzed using the BD CellQuest soft ware.
Statistical analysis
All the obtained data were statistically analyzed using one-way analysis of variance 
(ANOVA), followed by a post hoc test (Bonferroni test). The value of p ≤ 0.05 was taken as 
the criterion for a statistically signifi cant diff erence.
RESULTS AND DISCUSSION
Eff ect of surfactant on erythropoietin stability
Eff ect of the surfactant presence. – The eff ect of the presence of surfactant can be eluci-
dated by comparing the results obtained with both F4 and F12. Both formulations were of 
the same composition (glycine and glutamic acid) except that F4 contained 0.1 mg Tween 
20 while F12 did not contain any surfactant at all (Table I).
The initial EPO concentrations were 38.0 ± 1.9 and 33.1 ± 1.8 mg mL–1 for F4 and F12, 
respectively (Table II and Fig. 1). Aft er two months of storage at 25 and 40 °C, F12 exhibited 
statistically signifi cant (p > 0.05) reduction in EPO concentration compared to F4. The re-
sults determined by ELISA (Table III) also confi rmed this fi nding. This can be att ributed 
to the anti-adsorptive eff ect of the surfactant (Tween 20), which is in agreement with many 
reports in the literature (17, 21).
The SDS-gel images are shown in Fig. 2. A summary of the results is presented in 
Table IV. Neither aggregation nor degradation was seen for F4 at 25 °C. When stored at 
40 °C, both F4 and F12 showed aggregation aft er 30 days and only F4 showed degradation 
aft er 60 days.
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The anti-adsorbent eff ect induced by the presence of surfactant was att ributed to the 
rivalry between the protein and the surfactant on the interface, leading to smaller driving 
force for protein surface adsorption (22). This was also pointed out by Chen and Dickinson 
(23). They showed that gelatin was displaced from the oil/water interface by the addition 
Table I. The exact composition of each of the prepared EPO parenteral formulations
F1a F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 
EPO (μg) 40 40 40 40 40 40 40 40 40 40 40 40 40 
Mannitol (mg) 5 5 5 5 5 5 5 5 5 5 5 5 
Glycine (mg) 6 6 6 6 6 6 6 6 6 
Leucine (mg) 1.5 1.5 0.5 1.5 
Arginine (mg) 1.5 0.5 1.5 0.5 
Glutamic acid (mg) 1.5 0.5 1.5 8 1.5 1.5 
Tween 20 (mg) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Poloxmer NF 188 (mg) 0.1 
HSA (mg) 2.5 
a The volume of each formulation was adjusted to 1 mL with phosphate buff er saline (PBS).
Table II. The remaining EPO concentration determined by the Bradford method in EPO formulations, at 
diff erent time intervals, stored at 25 and 40 °C
Time
                  Day




25 40 25 40 25 40 25 40
F1 (C) a28.0±1.8 28.2±0.6 28.1±1.7 28.6±1.7 26.8±0.3 28.9±0.9 25.9±1.2 22.3±2.1 19.8±2.9 
F2 37.9±1.7 35.7±3.1 32.9±1.3 35.9±0.1 29.0±0.3 35.9±1.0 29.8±3.1 33.3±0.8 24.0±2.8 
F3 41.6±0.9 37.1±0.9 35.5±1.2 37.2±0.4 34.8±1.9 42.8±2.0 34.0±0.5 38.7±1.5 33.4±2.9 
F4 38.0±1.9 36.3±1.9 33.5±0.4 38.3±0.8 32.5±3.4 40.6±0.6 35.2±0.8 40.9±3.2 34.0±1.5 
F5 42.9±1.1 42.2±1.9 36.6±1.6 42.3±1.0 36.4±2.5 40.5±3.2 34.6±2.7 32.6±1.7 26.4±1.3 
F6 37.5±0.5 41.8±2.0 32.1±0.8 36.8±1.1 32.8±0.9 36.3±1.5 30.0±0.5 28.3±1.6 22.3±3.2 
F7 40.3±0.8 42.8±1.0 42.8±2.1 41.6±0.6 40.2±1.4 40.5±1.6 36.9±1.9 31.1±0.5 25.1±1.2 
F8 41.2±0.7 39.0±2.5 42.2±1.7 39.0±2.5 40.9±0.3 39.6±0.7 35.9±0.4 39.6±1.3 30.1±0.7 
F9 39.0±0.6 44.0±0.7 39.3±0.6 40.6±2.3 29.0±3.0 35.3±0.3 26.3±2.8 37.5±2.3 25.3±0.1 
F10 34.1±2.7 35.2±2.3 31.2±2.2 33.9±0.3 23.5±0.9 32.2±1.8 23.5±0.8 32.1±0.9 24.8±0.3 
F11 34.0±0.9 34.1±0.9 36.7±1.6 39.1±0.5 35.2±0.2 39.2±0.4 29.8±1.2 40.8±1.5 29.7±1.5 
F12 33.1±1.8 30.5±1.6 27.8±2.3 35.3±2.0 27.8±2.7 31.9±1.3 25.3±0.8 30.6±3.0 26.5±2.2 
a The remaining EPO concentration (μg mL–1), mean ± SD, n = 5.
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of a non-ionic surfactant (Tween 20). This eff ect also led to reduction in protein degrada-
tion as the surface tension was decreased. Surfactant concentration is vital for reducing 
both protein adsorption and damage. Randolph and Jones (22) recommended a surfactant 
concentration fairly higher than the critical micellar concentration (CMC) to provide pro-
tection against the harm induced by the protein adsorption on the interface.
Eff ect of surfactant type. – The eff ect of surfactant type on EPO stability was determined 
by comparing F4 (containing Tween 20) with F11 (containing poloxamer). Fig. 3 compares 
F4 and F11 regarding the amount of EPO remaining aft er the two-month storage at both 
25 and 40 °C. The initial EPO concentration for F11 (34.0 ± 0.9 mg mL–1) was signifi cantly 
lower (p > 0.05) than that obtained with F4 (38.0 ± 1.9 mg mL–1). For samples stored at 25 °C, 
EPO concentrations determined for both formulations at all time points were close, with 
statistically non-signifi cant diff erences. For samples stored at 40 °C, among all the samples 
of both formulations, only F11 samples, taken aft er 45 and 60 days suff ered a signifi cant 
loss of a magnitude of 29.8 ± 1.2 and 29.7 ± 1.5 mg mL–1, respectively. Gel images showed 
aggregation for all F11 samples stored at both temperatures but no degradation was de-
tected. In the case of F4, neither aggregation nor degradation was noticed for samples 
stored at 25 °C, while at 40 °C, aggregation was detected for 30, 45, and 60 days samples 
and degradation was observed only for the 60-day sample.
a)
b)
Fig. 1. Comparison between the remaining EPO concentrations for F4, F12 stored at: a) 25 °C, b) 40 °C 
for 60 days, determined by the Bradford method. Values represent mean ± SD, n = 5.
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The remaining concentrations determined by ELISA were much lower for F11 (polox-
amer) compared to F4 (Tween 20) at both storage temperatures, reaching a magnitude close 
to 10 mg mL–1. The increase in F11 EPO concentrations determined by the Bradford method 
upon storage may be att ributed to the possibility of interaction between the hydrophilic 
blocks of poloxamer with Coomassie giving an overestimated EPO concentration. This is 
evidenced by much lower concentrations obtained with ELISA for F11.
It was found that the benefi cial eff ects of Tween 20 were superior to that of poloxamer 
118. This may be att ributed to the diff erence in CMC between the two surfactants. The 
reported CMC of poloxamer 118 is 1 mg mL–1 while it is 0.0987 mg mL–1 for Tween 20 (24). 
The concentration of surfactant used in all formulations was 0.1 mg mL–1, which corre-
sponds to Tween 20 CMC but is lower than that of Poloxamer 118. This can explain the 
superiority of Tween 20, since the use of surfactants at a high concentration is not recom-
mended as it may alter protein stability (25).
Eff ect of amino acids on EPO stability
Eff ect of the amino acid presence. – It was evaluated by comparing the remaining EPO 
concentration of F1 (control with no amino acids and surfactants) with F12 (no surfactants 
but containing glycine and glutamic acid). Bradford results showed that F1 exhibited sig-
nifi cantly lower (p > 0.05) EPO concentration than F12 at all time points. However, the re-
Table III. The remaining EPO concentration determined by ELISA in EPO formulations, at diff erent time 
intervals, stored at 25 and 40 °C




25 40 25 40 25 40 25 40
F1 (control) 34.9±0.9a 34.2±0.9 26.3±1.3 34.4±0.8 22.7±3.8 25.9±1.2 19.1±1.2 25.9±1.3 23.7±1.0 
F2 35.7±0.3 41.9±0.9 23.0±2.0 37.0±0.3 15.7±0.3 30.3±1.1 14.0±0.7 33.3±4.2 14.7±0.6 
F3 36.2±1.8 40.6±0.1 18.5±1.9 37.8±1.8 11.0±2.9 29.0±2.2 12.8±1.4 34.8±2.8 10.5±1.6 
F4 39.8±2.7 42.4±0.6 19.5±2.4 39.8±2.7 16.4±2.2 33.9±1.4 15.1±0.8 34.6±4.1 14.5±0.5 
F5 39.2±1.3 36.2±2.2 14.7±1.7 38.0±1.5 12.0±0.7 24.1±0.1 6.3±0.2 20.9±1.2 3.8±0.1 
F6 37.5±0.1 40.0±3.8 19.8±1.6 38.7±1.7 13.0±1.0 27.0±0.2 14.7±1.3 21.7±0.8 8.6±0.6 
F7 42.1±0.1 37.0±1.3 17.4±0.8 38.2±1.0 9.2±0.1 26.0±0.3 9.0±0.6 21.5±0.5 3.6±0.1 
F8 44.2±4.1 37.0±0.3 15.5±1.2 38.9±1.0 6.7±0.3 29.1±0.5 5.9±0.1 22.1±0.9 2.8±0.2 
F9 39.3±2.0 27.8±0.5 9.9±0.4 32.9±1.4 7.7±0.4 27.2±4.7 2.9±0.1 27.1±4.6 3.5±0.4 
F10 35.6±2.5 26.7±0.7 10.9±1.3 29.6±1.1 7.5±0.2 27.8±1.3 3.9±0.2 27.4±1.2 3.8±0.8 
F11 34.9±3.3 33.7±1.2 28.3±2.3 31.2±1.5 22.0±1.6 28.5±2.2 10.3±1.0 10.3±1.0 10.0±1.5 
F12 31±0.9 27.1±1.6 19.1±2.4 24.1±1.2 16.1±1.6 23.4±2.5 13.5±0.7 24.3±2.1 9.5±0.1 
F13 33.0±1.7 26.6±3.1 20.9±0.1 28.2±3.5 21.8±0.7 24.4±0.9 13.9±0.3 13.3±0.9 12.2±2.8 
a The remaining EPO concentration (μg mL–1), mean ± SD, n = 5.
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Image of SDS gel electrophoresis   Image of SDS gel electrophoresis
Lane 1: Molecular mass marker   Lane 1: Molecular mass marker
Lane 2: F4 stored for 15 days at 40 °C  Lane 2: F2 stored for 30 days at 40 °C
Lane 3: F3 stored for 15 days at 40 °C  Lane 3: F2 stored for 30 days at 25 °C
Lane 4: F2 stored for 15 days at 40 °C  Lane 4: F1 stored for 30 days at 40 °C
Lane 5: F1 stored for 15 days at 40 °C  Lane 5: F1 stored for 30 days at 25 °C
Lane 6: F1 stored for 15 days at 25 °C
Image of SDS gel electrophoresis   Image of SDS gel electrophoresis
Lane 1: Molecular mass marker   Lane 1: F7 stored for 30 days at 25 °C
Lane 2: F4 stored for 15 days at 25 °C  Lane 2: F7 stored for 30 days at 40 °C
Lane 3: F3 stored for 15 days at 25 °C  Lane 3: F8 stored for 30 days at 25 °C
Lane 4: F2 stored for 15 days at 25 °C  Lane 4: F8 stored for 30 days at 40 °C
        Lane 5: Molecular mass marker
Image of SDS gel electrophoresis   Western-blot image
Lane 1: Molecular mass marker   Lane (1): F1 stored for 60 days at 40 °C.
Lane 2: F9 stored for 60 days at 25 °C   Lane (2): F2 stored for 60 days at 40 °C.
Lane 3: F9 stored for 60 days at 40 °C   Lane (3): F3 stored for 60 days at 40 °C.
Lane 4: F10 stored for 60 days at 25 °C   Lane (4): F4 stored for 60 days at 40 °C
Lane 5: F10 stored for 60 days at 40 °C
Fig. 2. Gel images of some EPO formulations.
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sults obtained by ELISA showed signifi cant by lower (p > 0.05) concentration for F12 at a 
number of time points. The SDS gel images revealed aggregation only for samples stored 
at 40 °C for both formulations and degradation bands were reported only for F1 samples 
when stored at 40 °C.
Eff ect of the amino acid type. – Formulation development followed a number of sequenc-
es in order to explore the possible role of the amino acid type in the stabilization of EPO. 
The eff ect of glycine was studied initially since it is extensively used as a stabilizer in a 
number of EPO formulation patents (21, 26).
F4 and F9 were selected to evaluate the eff ect of glycine, since F9 is of the same com-
position as F4 except for the absence of glycine. Both Bradford and ELISA results revealed 
no signifi cant diff erence in most points between the two formulations when they were 
stored at 25 °C, while for samples stored at 40 °C, F4 generally had signifi cantly higher 
(p > 0.05) EPO content than F9. The gel electrophoresis images showed that the presence of 
glycine in F4 resulted in resistance to aggregation and degradation at 25 °C and delay of 
both of them at 40 °C compared to F9.
Eff ect of amino acid combinations. – The second step was to examine the eff ect of using 
diff erent amino acid combinations. Three amino acids, leucine, arginine and glutamic 
acid, were selected to represent neutral, alkaline, and acidic amino acid, respectively. F2 
a)
b)
Fig. 3. Comparison between the remaining EPO concentrations for F4 and F11 stored at: a) 25 °C, b) 40 °C, 
for 60 days, determined by the Bradford method. Values represent mean ± SD, n = 5.
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(glycine and arginine), F3 (glycine and leucine), F4 (glycine and glutamic acid), F8 (gly-
cine alone) were selected. The values of the remaining EPO concentrations based on the 
ELISA technique were generally lower than those determined by the Bradford method 
for the four formulations, especially for samples stored at 40 °C, but they followed the 
same trend. Only with F4, neither aggregation nor degradation bands were noticed when 
stored at 25 °C while the other three formulations showed aggregation sometimes ac-
companied with degradation at various stages. In general, the results indicated that the 
amino acid type had a role in protecting against aggregation and the combination of 
glycine with glutamic acid (F4) was much bett er than glycine alone or its combination 
with leucine or arginine.
The third strategy was to study the eff ect of applying a combination of more than one 
amino acid type with glycine. In this regard, three formulations F5 (leucine + arginine, 3:1), 
F6 (leucine + arginine, 1:3) and F7 (leucine + arginine + glutamic acid, 3:1:1) were formu-
lated and tested. The results of the Bradford method showed that all the three formulations 
suff ered signifi cant loss in the EPO concentration at the last time points (aft er 60 days at 
both storage temperatures) and F6 comprised the lowest EPO magnitude among them. The 
results obtained by the ELISA method were close to those obtained by the Bradford meth-
od for 25 °C samples while they were extremely lower for 40 °C samples. The gel images 
showed that all the three formulations showed aggregation bands aft er 30 days of storage 
at both temperatures but no degradation bands appeared for all the tested samples. Com-
pared with F4, it is clear that F4 was superior to the three formulations, exhibited higher 
Table IV. Summary of SDS-gel electrophoresis results for formulations stored at 25 and 40 °C




25 40 25 40 25 40 25 40
F1 – – – A, D A A, D A A, D 
F2 – D A A, D A A, D A A, D 
F3 – A, D A A, D – A – A, D 
F4 – – – A – A – A, D 
F5 – – A A A A A A 
F6 – – A A A A A A 
F7 – – A A – A A A 
F8 – – A A A A A A 
F9 A A A A A A, D A A, D 
F10 A A A A A A A A, D 
F11 A A A A A A A A 
F12 – – A A A A A A 
A – aggregation, D – degradation, (–) – refers to the absence of aggregation or degradation.
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EPO concentrations at both temperatures and showed higher resistance against aggrega-
tion. However, the three formulations were more protected against degradation.
The fourth step was to explore the eff ect of using diff erent concentrations of glutamic 
acid alone. Two formulations, F9 (1.5 mg mL–1) and F10 (8 mg mL–1), were prepared. It is 
clear that signifi cant loss in the EPO concentration initially occurred in the case of F10 and 
both formulations suff ered higher rates of EPO loss compared to F4 at both temperatures. 
Gel images showed early detection of aggregation bands, starting from the fi rst sample 
(day 15) while no degradation bands were seen in the samples, except for F9 aft er 45 days 
and F10 aft er 60 days of storage at 40 °C. It is concluded that glutamic acid alone was not 
useful and did not provide reasonable protection against adsorption and aggregation.
Human serum albumin versus amino acids. – F13, containing HSA, was not evaluated 
by the Bradford method and SDS-gel electrophoresis due to the interference caused by 
HSA with EPO. The molecular size of HSA would interfere with the band referring to 
aggregation in the case of the gel electrophoresis method and with color change induced 
by EPO in case of the Bradford method. The results obtained by ELISA showed that the 
initial EPO concentration (0 day sample) was signifi cantly lower than in most of the for-
mulations (F4, F5, F6, F7, F8 and F9) and very close to F1 (control). The remaining EPO 
concentration decreased with the increase in storage time at 25 °C, reaching a value of 
13.3 ± 0.9 μg mL–1. All the determined concentrations were lower than the corresponding 
concentrations obtained with F1. Aft er storage at 40 °C, the determined concentrations 
shift ed to lower values closing at 12.2 ± 2.8 mg mL–1.
F1 (control), F2 (glycine and arginine), F3 (glycine and leucine) and F4 (glycine and 
glutamic acid) stored for 60 days at 40 °C were analyzed using the Western-blot method. 
These samples were chosen because their SDS images showed clear aggregated and de-
graded bands. Full polyvinylidene difl uoride (PVDF) membrane images (Fig. 2) showed 
clearly bands for aggregated, degraded and pure EPO.
The eff ect of the amino acid properties on the stabilization of EPO was explored here 
for the fi rst time by using diff erent combinations of neutral, anionic and cationic amino 
acids. The results showed that the use of combinations was much bett er than using single 
amino acids. F4 (combination of glycine and glutamic acid) showed higher stability than 
F8 (glycine alone) and F9 and F10 (glutamic acid alone). Only a few patents are available 
in the literature for the use of diff erent amino acids as EPO stabilizers. Choi et al. (27) 
introduced a stable EPO formulations containing Tween 20, glycine, propylene glycol and 
mannitol. They claimed stability of the formulation aft er 5 weeks of storage at 25 and 37 
°C using size exclusion chromatography. The recovery was 93 % aft er storage at 37 °C for 
5 weeks, with no detection of dimmers. However, this study did not evaluate the degrada-
tion of EPO. Another EPO formulation, containing L-histidine and Tween 80, was pre-
sented by Yamazaki et al. (17). They showed that a recovery of 99 % was achieved when 
the formulation was stored for 2 weeks at 40 °C and 6 months at 25 °C using RP-HPLC 
and SDS-gel electrophoresis. The authors claimed no EPO degradation for samples stored 
at 40 °C, but nothing was said about degradation of samples stored at 25 °C, and the sta-
bility of the formulation against aggregation was never addressed. The application of as 
elevated temperature of 40 °C for accelerated stability testing appeared to be very harsh 
for EPO as all the formulations showed either aggregation or degradation and some for-
mulation showed both.
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The discrepancy between the results obtained by ELISA and Bradford can be ex-
plained by the principle of the ELISA test that depends upon the reaction between the 
specifi c EPO antibody and certain epitope in the EPO molecule. In the case of aggrega-
tion, some of the epitopes will be covered and not disclosed to the antibody, resulting 
in smaller amounts in the determined concentration compared to the corresponding 
concentrations determined using the Bradford method. Since their gel electrophoresis 
images showed aggregation bands, this explains the signifi cantly lower concentrations 
determined by ELISA for F5-F12 stored at 25 °C compared to the corresponding concen-
trations determined by Bradford method. On the other hand, the absence of aggrega-
tion bands for F4 (glycine and glutamic acid) was accompanied by closer concentrations 
determined by both methods at 25 °C. The tremendously lower ELISA-determined con-
centrations exhibited for all the formulations when stored at 40 °C are att ributable to 
the presence of aggregation bands at all time points. However, in the case of degrada-
tion, the ELISA-determined concentrations may not be aff ected as long as the epitope is 
exposed. The results obtained by Western blot allowed this conclusion, since the spe-
cifi c EPO antibody used for ELISA reacted with both the aggregation and degradation 
bands as well as with the original EPO band. Higher ELISA determined concentration 
for F1 (control) aft er 60 days at 40 °C compared with the corresponding concentration 
obtained by the Bradford method can be explained by the degradation proven by gel 
electrophoresis leading to the over-expression of EPO concentration. Thus, one can con-
clude that ELISA cannot be considered as a stability indicating assay and, probably, this 
is the reason for not including it in the EPO analytical tests recommended by the Euro-
pean Pharmacopoeia (20).
The optimum formulation
It was clear that among all the tested formulations F4 (containing glycine and glu-
tamic acid together with Tween 20) was the best formulation, since it retained a high con-
centration of EPO with minimum loss aft er a two-month storage at 25 °C. Their SDS-gel 
images showed neither aggregation nor degradation bands and the ELISA determined 
concentrations were comparable with those determined by the Bradford method. In com-
parison with F13 (containing HSA), F4 was superior, with signifi cantly higher concentra-
tions at all time points for samples stored at 25 °C.
In vivo bioassay
F4 was selected for this part because it was previously shown as the most stable 
among all the prepared formulations. The average reticulocytes to red blood cells ratio 
obtained with the negative control group (received only PBS) was 0.13 ± 0.02, while values 
of 0.33 ± 0.06 and 0.27 ± 0.03 were achieved with both positive control groups receiving 
pure EPO solution in PBS and Eprex®, respectively. The average reticulocytes to red blood 
cells ratio obtained with the animal group receiving F4 was 0.33 ± 0.04. Statistical analysis 
showed that there was no signifi cant diff erence between F4, pure EPO solution and Eprex®, 
at p > 0.05. This indicates that F4, the formulation showing high in vitro stability, has prov-
en to be active in vivo and the constituents of the formulation did not aff ect the physiolog-
ical activity of EPO.
81




The study revealed that the presence of surfactants is important to enhancing EPO 
stability by reducing adsorption on the surfaces of containers and the tendency of aggrega-
tion. However, they may also enhance the degradation rate. Further, the surfactant type is 
a considerable factor in the formulation of an EPO stable formulation, so Tween 20 is more 
eff ective than Poloxamer 118 in the protection of EPO against adsorption and aggregation, 
while Poloxamer 118 may provide more protection against degradation than Tween 20. 
Also, the presence of amino acids may reduce the magnitude of EPO adsorption and the 
amino acid type has a role in the protection of EPO, since the combination of glycine with 
glutamic acid was much bett er than glycine alone or its combination with leucine or argi-
nine.
Another point is that ELISA cannot be regarded as a stability indicating assay because 
degraded protein can be determined. The diligence of the storage condition at 40 °C as 
elevated temperature for accelerated stability testing appeared to be very harsh for EPO as 
all the formulations showed either aggregation or degradation, while some formulations 
showed both. Finally, there is no single analytical technique that can be used for the eval-
uation of protein in general and the use of gel electrophoresis is highly recommended for 
explaining the signifi cance of ELISA results.
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